Back to portfolio
This program focuses on the validation of USP15, a novel target in neuroinflammation. This project also aims to identify additional inflammation-related indications in which modulating the activity of USP15 could prove beneficial. This program, led by Dr. Philippe Gros from McGill University, has been spun out into Corbin Therapeutics; an AmorChem start-up company.